Indaptus Therapeutics, Inc. (INDP)
NASDAQ: INDP · Real-Time Price · USD
0.5150
-0.0349 (-6.35%)
At close: Apr 1, 2025, 4:00 PM
0.5580
+0.0429 (8.34%)
After-hours: Apr 1, 2025, 4:38 PM EDT
Company Description
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.
Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.
Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Indaptus Therapeutics, Inc.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jeffrey Meckler |
Contact Details
Address: Three Columbus Circle, 15th Floor New York, New York 10019 United States | |
| Phone | 646 427 2727 |
| Website | indaptusrx.com |
Stock Details
| Ticker Symbol | INDP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001857044 |
| CUSIP Number | 45339J105 |
| ISIN Number | US45339J1051 |
| Employer ID | 86-3158720 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey A. Meckler J.D. | Chief Executive Officer and Director |
| Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer and Director |
| Walt Addison Linscott Esq. | Chief Operating Officer |
| Dr. Roger J. Waltzman M.B.A., M.D. | Chief Medical Officer |
| Nir Sassi | Chief Financial Officer, Secretary and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2025 | EFFECT | Notice of Effectiveness |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 13, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 13, 2025 | 10-K | Annual Report |
| Feb 18, 2025 | SCHEDULE 13G | Filing |
| Feb 13, 2025 | EFFECT | Notice of Effectiveness |
| Feb 12, 2025 | UPLOAD | Filing |
| Feb 12, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Feb 12, 2025 | 8-K | Current Report |
| Feb 11, 2025 | EFFECT | Notice of Effectiveness |